MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Neumora Therapeutics, Inc. (NMRA)*
Organization & Developments: Neumora Therapeutics
Parents
Neumora Therapeutics, Inc. (NMRA)*
Children
*Platform integrates multiple types of data to create Data Biopsy Signatures™ and Precision Phenotypes™ to map disease drivers to the defined patient subtypes.
2022: The company, codenamed Really Big Neuroscience Company by its bankrollers at Arch Venture Partners, is a rollup of firms with projects in anxiety, autism, eating disorders, and neu
2022: Vanderbilt Strikes Precision Medicine Partnership to Fight Brain Diseases
2023: Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades
2023: Neumora: Novel Neuroscience Player, But Valuation Is Too High_seekingalpha.com
2024: Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans
2024: Neumora Therapeutics' SWOT analysis: stock's potential in depression treatment market Investing.com
2024: Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
2024: Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling
2024: Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits
2025: Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops
2025: Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Jumps
Finance & Acquisitions: Neumora Therapeutics
Key People: Neumora Therapeutics